1276197-26-2
1276197-26-2
Chemical Structure
Chlorotrianisene-d9
- CAS No.: 1276197-26-2
- Formula:C23H12D9ClO3
- Molecular Weight:389.92
IUPAC Name: 4,4',4''-(2-chloroethene-1,1,2-triyl)tris((methoxy-d3)benzene)
InChIKey: BFPSDSIWYFKGBC-GQALSZNTSA-N
SMILES: Cl/C(C1=CC=C(C=C1)OC([2H])([2H])[2H])=C(C2=CC=C(C=C2)OC([2H])([2H])[2H])\C3=CC=C(C=C3)OC([2H])([2H])[2H]
Biological Activity: Chlorotrianisene-d9 is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Chlorotrianisene-d9 | Chlorotrianisene-d9 is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chlorotrianisene (Standard) | ≥98% | Chlorotrianisene (Standard) is the analytical standard of Chlorotrianisene. This product is intended for research and analytical applications. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chlorotrianisene | 99.02% | Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Ruenitz PC, et al. Estrogenic tamoxifen derivatives: categorization of intrinsic estrogenicity in MCF-7 cells. J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):203-9. [Content Brief]
- [3]. Lounkine E, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012 Jun 10;486(7403):361-7. [Content Brief]
